Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 5 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Results 1 - 20 of 362 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar luremaster (35.83) Submitted: 12/18/2014 3:28:20 AM : Outperform Start Price: $104.47 GILD Score: +2.94

High quality, huge growth, low price

Recs

0
Member Avatar 1badbeerad (32.42) Submitted: 12/16/2014 6:18:24 PM : Outperform Start Price: $100.26 GILD Score: +4.17

Wow, what a solid pick. One you shouldn't worry about. Just come back in 5 years and pick up a check.

Recs

0
Member Avatar RW (54.01) Submitted: 12/15/2014 2:46:15 PM : Outperform Start Price: $102.95 GILD Score: +2.04

Gilead has a long track record for homeruns so I want to invest in their future. This seems like a good price too as the share price has been steadily dropping (which has caused me some short-term heart burn as I bought right before the drop.)

Recs

0
Member Avatar goLongWpicks (82.30) Submitted: 12/12/2014 3:49:11 PM : Outperform Start Price: $105.24 GILD Score: +0.80

Leader in HIV therapeutics and new Hep C drug is a blockbuster. Stock priced at 17x trailing non-GAAP eps. Looks cheap.

Recs

0
Member Avatar NuclearSteve (72.70) Submitted: 12/11/2014 10:48:13 AM : Outperform Start Price: $106.73 GILD Score: +1.29

Barron's article says stock is still cheap at roughly 10.5 times next years earnings while S&P trading at 17 times next years earnings.

Recs

0
Member Avatar Carvski (73.48) Submitted: 12/10/2014 12:17:11 AM : Outperform Start Price: $105.89 GILD Score: +2.12

Growth at a reasonable price. Target = $140 mid-2015.

Recs

0
Member Avatar coleman205 (20.99) Submitted: 12/1/2014 11:29:05 PM : Outperform Start Price: $101.17 GILD Score: +6.85

great lineup. huge earnings growth potential

Recs

1
Member Avatar Haiphen (< 20) Submitted: 11/23/2014 7:58:59 AM : Outperform Start Price: $101.11 GILD Score: +7.57

Looks like great value for such a high-growth stock. Low PE and Low PEG.

Recs

0
Member Avatar TMFInnovator (42.90) Submitted: 11/23/2014 1:02:51 AM : Outperform Start Price: $101.11 GILD Score: +7.57

A powerhouse with Sovaldi and still an extremely strong pipeline. Think that Gilead continues to outperform.

Recs

0
Member Avatar littleoldmedng (< 20) Submitted: 11/21/2014 10:54:52 AM : Outperform Start Price: $100.64 GILD Score: +7.99

Good Value and bound to rebound. Time to get in

Recs

0
Member Avatar cmrk3 (27.86) Submitted: 11/19/2014 10:14:13 AM : Outperform Start Price: $39.82 GILD Score: +135.14

Saving lives through selling expensive medicine.

Recs

0
Member Avatar TMFTiptree (34.50) Submitted: 11/14/2014 2:14:41 PM : Outperform Start Price: $101.60 GILD Score: +5.47

Innovative company with a strong pipeline of drugs, plus a blockbuster gaining momentum.

Recs

0
Member Avatar purplehayes4 (54.81) Submitted: 11/8/2014 7:09:24 AM : Outperform Start Price: $109.07 GILD Score: -2.11

R&D seems to be their strong suit. Will be a leader for many years to come.

Recs

0
Member Avatar jdbow (61.27) Submitted: 11/7/2014 10:47:20 AM : Outperform Start Price: $98.43 GILD Score: +0.72

needed a drug company in my portfolio and this look like a good one

Recs

0
Member Avatar natureperfect7 (< 20) Submitted: 10/31/2014 1:19:17 AM : Outperform Start Price: $109.91 GILD Score: -3.80

The produce is much needed and is successful.

Recs

0
Member Avatar JeffRossMD (< 20) Submitted: 10/30/2014 12:44:05 PM : Outperform Start Price: $113.70 GILD Score: -8.44

The biotech space is just heating up as new technologies are revolutionizing cancer and chronic disease processes.

Recs

0
Member Avatar bartlettmi (70.69) Submitted: 10/29/2014 12:57:20 PM : Outperform Start Price: $109.65 GILD Score: -5.36

Not just a Hep-C company... This stock's run is not over.

Recs

0
Member Avatar lernout1973 (48.90) Submitted: 10/29/2014 6:01:29 AM : Outperform Start Price: $109.85 GILD Score: -5.29

strong growth, generates massive cash, good chance/risk ratio

Recs

0
Member Avatar rpd5 (< 20) Submitted: 10/28/2014 9:15:41 PM : Outperform Start Price: $99.67 GILD Score: +9.16

Solvadi continues to sell well

Recs

0
Member Avatar Deepvaluestocks (< 20) Submitted: 10/27/2014 4:40:05 PM : Outperform Start Price: $113.25 GILD Score: -9.17

GILD had the best in class treatment for Hepatitis C in Harvoni and trades at a forward PE under 13, which is very low considering the potential growth.

Featured Broker Partners


Advertisement